Zobrazeno 1 - 10
of 127
pro vyhledávání: '"Som D. Mukherjee"'
Autor:
Sandeep R. Sehdev, Nigel S. B. Rawson, Olexiy I. Aseyev, Catriona J. Buick, Marcus O. Butler, Scott Edwards, Sharlene Gill, Joanna M. Gotfrit, Cyrus C. Hsia, Rosalyn A. Juergens, Mita Manna, Joy S. McCarthy, Som D. Mukherjee, Stephanie L. Snow, Silvana Spadafora, David J. Stewart, Jason R. Wentzell, Ralph P. W. Wong, Pawel G. Zalewski
Publikováno v:
Current Oncology, Vol 31, Iss 4, Pp 1803-1816 (2024)
Patient access to new oncology drugs in Canada is only possible after navigating multiple sequential systemic checkpoints for national regulatory approval, health technology assessment (HTA) and collective government price negotiation. These steps de
Externí odkaz:
https://doaj.org/article/3be7b57ba6b54e2e8cadf719163522c8
Autor:
Peter A. Kavsak, PhD, Brock Hoard, BHSc, Katharine Mackett, BSc, MSc, Som D. Mukherjee, MD, MSc, Louise Bordeleau, MD, MSc, Peter M. Ellis, MD, PhD, Sukhbinder Dhesy-Thind, MD
Publikováno v:
CJC Open, Vol 5, Iss 8, Pp 658-660 (2023)
Externí odkaz:
https://doaj.org/article/af4d9c3fb61a4c839a48e48aeb3589d3
Publikováno v:
Current Oncology, Vol 29, Iss 12, Pp 9801-9812 (2022)
Purpose: To determine the prevalence and content of discussions regarding physical activity (PA) promotion between individuals with a current or past diagnosis of cancer and their oncology care team. Methods: Design and Procedure: A cross-sectional s
Externí odkaz:
https://doaj.org/article/0444c425052d4707b8f6e699b4c385a8
Autor:
Muhammad Mustafa Alhussein, MD, Abir Mokbel, MD, MSc, Tammy Cosman, RN(EC), PhD, Nazanin Aghel, MD, Eric H. Yang, MD, Som D. Mukherjee, MD, Susan Dent, MD, Peter M. Ellis, MBBS, MMed, PhD, Sukhbinder Dhesy-Thind, MD, MSc, Darryl P. Leong, MBBS, MPH, M. Biostat, PhD
Publikováno v:
CJC Open, Vol 3, Iss 11, Pp 1372-1382 (2021)
Background: Human epidermal growth factor receptor 2 (HER2) overexpressing malignancies, including breast and gastro-esophageal, are associated with a poor prognosis. The cardiotoxicity of trastuzumab, a HER2-targeting monoclonal antibody, is well es
Externí odkaz:
https://doaj.org/article/19ebfb6c8fb04bf8886b70411a949d57
Autor:
Darryl P. Leong, MBBS, MPH, MBiostat, PhD, Tammy Cosman, PhD, Muhammad M. Alhussein, MD, Nidhi Kumar Tyagi, MBChB, Sarah Karampatos, MS, Carly C. Barron, MD, MS, Douglas Wright, MD, Vikas Tandon, MD, Patrick Magloire, MD, Philip Joseph, MD, David Conen, MD, MPH, P.J. Devereaux, MD, PhD, Peter M. Ellis, MBBS, MMed, PhD, Som D. Mukherjee, MD, MS, Sukhbinder Dhesy-Thind, MD, MS
Publikováno v:
JACC. CardioOncology, Vol 1, Iss 1, Pp 1-10 (2019)
Objectives: This study sought to evaluate the safety of continuing trastuzumab in patients with human epidermal growth factor receptor–positive breast cancer who developed mild cardiotoxicity. Background: Cardiotoxicity is the most common dose-limi
Externí odkaz:
https://doaj.org/article/853ece99bece43b0bf1ea0e673d30148
Autor:
Som D. Mukherjee, Nicole Hodgson, Peter J. Lovrics, Kavita Dhamanaskar, Terry Minuk, Shelley Chambers, Jonathan Sussman
Publikováno v:
Breast Cancer: Basic and Clinical Research, Vol 2016, Iss 10, Pp 53-60 (2016)
Externí odkaz:
https://doaj.org/article/d7ecb475aa9d40f3be715f9242a0efb3
Autor:
Darryl P. Leong, Som D. Mukherjee
Publikováno v:
JACC: CardioOncology. 5:137-140
Autor:
Filipe Cirne, Coralea Kappel, Shijie Zhou, Som D. Mukherjee, Mahshid Dehghan, Jo-Anne Petropoulos, Darryl P. Leong
Publikováno v:
Prostate Cancer and Prostatic Diseases. 25:453-462
Most of the epidemiological data on prostate cancer risk factors come from high-income countries (HIC). Reducing exposure to prostate cancer modifiable risk factors may significantly lower PCa morbidity and mortality in LIC and MIC. The objective of
Autor:
Shijie Zhou, Filipe Cirne, Justin Chow, Arman Zereshkian, Louise Bordeleau, Sukhbinder Dhesy-Thind, Peter M Ellis, Som D Mukherjee, Nazanin Aghel, Darryl P Leong
Publikováno v:
The Oncologist.
Introduction Cardiotoxicity, manifest by reduced left ventricular ejection fraction (LVEF), is the most common reason for the premature discontinuation of trastuzumab. While permissive cardiotoxicity (where mild cardiotoxicity is accepted to enable o
Autor:
Ronan Foley, Yves Fradet, Louis Lacombe, Rafick-Pierre Sekaly, Jean Gariepy, Jeffery Gaudet, Paula J. Foster, Corby Fink, Gregory A. Dekaban, Som D. Mukherjee, Sebastien Hotte, Claire Landry, Yoav Peretz, David Favre, Bader Yassine-Diab, Robin Eady, Russell D. Salter, Olivera J. Finn, Alain Bergeron, Pierre Major, Elizabeth Scheid
Legends of Supplementary Figures S1 to S6
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bb251d4037fa924b5a3a2838858c79a2
https://doi.org/10.1158/2326-6066.22538168.v1
https://doi.org/10.1158/2326-6066.22538168.v1